Drugmaker Daiichi Sankyo has risen the most in five months after its novel breast cancer treatment won U.S. approval, a milestone in the company’s efforts to turn it into a widely used blockbuster.

Following a world-first approval in Japan, AstraZeneca and Daiichi Sankyo’s second antibody-drug conjugate has crossed the U.S. regulatory finish line. The FDA has greenlighted the drug ...

Japan's health ministry said on Friday it agreed to buy 1.4 million doses of Daiichi Sankyo's updated COVID-19 vaccine. The purchase is contingent on approval of the shot formulated for the XBB.1. ...

Daiichi Sankyo had opposed the open offer made in 2018 after Northern TK Venture had acquired a 31% stake in Fortis. NTK had then filed a lawsuit against Daiichi Sankyo in November 2023.

TOKYO & BASKING RIDGE, N.J., January 13, 2025--(BUSINESS WIRE)--Daiichi Sankyo Company, Ltd (TSE: 4568) announced today that it will pay Glycotope $132.5 million to acquire intellectual property ...

Malaysia's IHH Healthcare said on Thursday its unit is seeking compensation of up to 109.3 billion rupees ($1.25 billion) from Japan's Daiichi Sankyo for its stake buy in India's Fortis Healthcare.

PETALING JAYA: IHH Healthcare Bhd says its unit is seeking compensation of up to 109.3 billion rupees (RM5.46bil) from Japan’s Daiichi Sankyo for its stake buy in India’s Fortis Healthcare.